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During the perinatal period, free radicals (FRs) are involved in several physiological roles such as the cellular responses to noxia, the
defense against infectious agents, the regulation of cellular signaling function, and the induction of a mitogenic response. However,
the overproduction of FRs and the insuﬃciency of an antioxidant mechanism result in oxidative stress (OS) which represents a
deleterious process and an important mediator of damage to the placenta and the developing fetus. After birth, OS can be
magniﬁed by other predisposing conditions such as hypoxia, hyperoxia, ischemia, hypoxia ischemia-reperfusion, inﬂammation,
and high levels of nonprotein-bound iron. Newborns are particularly susceptible to OS and oxidative damage due to the
increased generation of FRs and the lack of adequate antioxidant protection. This impairment of the oxidative balance has been
thought to be the common factor of the so-called “free radical related diseases of prematurity,” including retinopathy of
prematurity, bronchopulmonary dysplasia, intraventricular hemorrhage, periventricular leukomalacia, necrotizing enterocolitis,
kidney damage, and oxidative hemolysis. In this review, we provide an update focused on the factors inﬂuencing these diseases
reﬁning the knowledge about the role of OS in their pathogenesis and the current evidences of such relationship. Mechanisms
governing FR formation and subsequent OS may represent targets for counteracting tissue damage.
1. Introduction
Each molecule is characterized by a particular concentration
of electrons that establish its own redox state. When speciﬁc
conditions occur, the redox state can be altered to lower or
higher levels thus forming free radicals (FRs) [1]. FRs are
highly reactive substances that are capable to start self-
ampliﬁed chain reactions causing cellular dysfunction and
damage. Many antioxidant enzymes exist to counteract this
propagation, and when the production of FRs exceeds the
capacity of scavenger defenses, an oxidative stress (OS)
occurs [2].
In the perinatal period, a properly controlled oxidative
species production has been proven to be a necessary factor
[3]. After fertilization, the beneﬁcial eﬀects of FRs occur at
low/moderate concentrations and involve physiological roles
in sperm capacitation, acrosome reaction, sperm-egg inter-
action, and gamete fusion [4, 5]. Until the beginning of
the second trimester, fetal development takes place in a
low-oxygen environment presumably to protect the embryo,
which is highly sensitive to reactive oxygen species (ROS) [6].
Subsequently, due to the placental maturation, a threefold
rise in the oxygen concentration causes an exponential
increase of ROS [7]. In this phase, ROS regulate gene
transcription and downstream activities such as trophoblast
proliferation, invasion, and angiogenesis. OS-induced apo-
ptosis inﬂuences placental vascular modiﬁcations [8],
induces autophagy, and together ensures the normal cellular
turnover until the late gestation [7]. The placenta adapts
to the increase in ROS generation by modulating
hypoxia-inducible factor 1α (HIF-1α) and increasing cellu-
lar antioxidant levels [9]. Under normal conditions, such
adaptation mechanisms must occur to ensure a proper
fetal development [10]. However, in a scenario where OS
is abnormally increased, chelation mechanisms may be
insuﬃcient and damage aﬀecting both the fetus and the
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mother can be observed. Many studies have shown a rela-
tionship between increased OS levels and several pregnancy
diseases, including defective embryogenesis, spontaneous
abortion, preeclampsia, intrauterine growth restriction, ges-
tational diabetes mellitus, premature rupture of membranes,
and minor congenital abnormalities [3, 9, 10–12].
The intrauterine environment and redox state can
also play a role for future diseases in the child such as
obesity and diabetes mellitus and hypertension in adult-
hood [13–15]. Finally yet importantly, an increased oxida-
tive level in the perinatal life may trigger a deleterious state
of OS in the newborn, especially in preterm infants, which
is capable to activate underlying mechanisms that lead to
the onset of the so-called “oxidative stress-related diseases
in newborn” [16–18]. The present review intends to make a
journey into the free radical chemical biology and to update
the current knowledge about the role of OS in the pathogen-
esis of such gestational, fetal, and neonatal diseases.
1.1. Free Radical Chemical Biology. Free radical reactions are
a normal occurrence in living organisms, and ROS are deeply
involved in signaling molecules to regulate a wide variety of
physiological events.
There are diﬀerent FR species: oxygen-centred radicals
(ROS), nitrogen-centred radicals (RNS), carbon-centred
radicals, and sulphur-centred radicals [19]. Intracellular gen-
eration of ROS can occur as a byproduct with mitochondria,
peroxisomes, cytochrome P450, and other cellular elements
(Figure 1(a)). ROS generation by mitochondria is a highly
variable and depends both from metabolic conditions
and the intramitochondrial balance between oxidative and
antioxidative factors.
Under physiologic conditions, approximately 98% of O2
undergoes a complete reduction to form H2O2. Approxi-
mately, 2% of electrons will leak causing a partial reduction
of O2-producing ROS [20]. The monovalent reduction of
O2 produces superoxide anion (O
−), and monovalent reduc-
tion of O− generates hydrogen peroxide (H2O2). A third
monovalent reduction generates the highly reactive hydroxyl
radical (OH•) [21, 22].
Any damage to the energy-producing machinery of the
mitochondria will result in superoxide accumulation, and
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Figure 1: Cellular sources of free radicals (a); antioxidant protection within the cell (b).
2 Oxidative Medicine and Cellular Longevity
any process that results in depletion of antioxidant defense
will result in the default conversion of superoxide to even
more oxygen reactive species.
Other important FR cellular sources are the following: the
activity of monoamine oxidase, which deaminates biogenic
amines and produces hydrogen peroxide (H2O2); the purine
catabolism by xanthine oxidase (XO), producing superoxide
anion radical (O2
−); the Haber-Weiss and Fenton reactions
by nonprotein-bound iron (NPBI) producing the hydroxyl
radical (OH); peroxynitrite (ONOO–) generator enzymes,
such as xanthine oxidoreductase, nicotinamide adenine
dinucleotide phosphate oxidase (Nox), nitric oxide synthase
(NOS), and heme oxygenase (HO) [23]; and the inﬂamma-
tory response where the production of H2O2 and O2
•−
increases in white blood cells and Kupﬀer cells due to
NADPH-dependent oxidase system, coupled to the action
of superoxide dismutase (SOD).
Aerobic organisms have developed well-integrated
antioxidant defenses to enable them to handle and scavenge
FRs [24] (Figure 1(b)). These defenses include antioxidant
enzymes and low molecular weight antioxidant compounds
like vitamins A, E, and C, beta-carotene, lipoic acid, and
glutathione. The antioxidant enzymes, like SOD, catalase,
and GPX, have the capacity to scavenge the levels of ROS
produced ever in physiological conditions [25]. Under
ischemic conditions, these antioxidant enzymes fail to pro-
tect tissue from oxidative damage because of the overproduc-
tion of oxygen radicals and consumptions of antioxidant
defense [25].
Once generated, the condition of OS may perpetuate the
damage to all components of the cell, including proteins,
lipids, and DNA. F2-isoprostanes (F2-IsoPs) are prostaglan-
din F2-like compounds derived by the FR peroxidation of
arachidonic acid. They are recognized as reliable marker of
lipid peroxidation. Docosahexaenoic acid (DHA), a major
component in neuronal membranes, oxidizes both in vitro
and in vivo to form F2-IsoP-like compounds termed F4-
neuroprostanes (F4-NPs) [16, 26–29]. An oxygen insertion
step diverts intermediates from the IsoP pathway to form
isofurans (IsoFs) that contain a substituted tetrahydrofuran
ring. Because of this diﬀerential method of formation, it
has been focused that oxygen concentration can aﬀect
lipid peroxidation proﬁle. Like the IsoPs, the IsoFs are
chemically and metabolically stable so are well suited to
act as in vivo biomarkers of oxidative damage. The NPs
are the only quantitative in vivo biomarker of oxidative
damage that is selective for neurons. An alternative path-
way of oxidation of DHA brings to the formation of an
IsoF-like compound termed neurofurans (NFs). Quantita-
tive assessment of NFs in vivo reveals modulated forma-
tion under conditions of elevated and diminished OS
[28]. Proteins are also vulnerable to FR attacks. Similar
to lipid peroxides, altered protein molecules, such as pro-
tein peroxides and protein-bound reducing moieties, can
act as traps for the chemical energy released by FR. Then
they can initiate further radical chain reactions, thus
enhancing the damage. Advanced oxidative protein products
(AOPP) are reliable markers of the degree of protein damage
in OS [30, 31].
In term of increased NPBI concentration, the link
between increased FR release and OS during fetal/neonatal
asphyxia has emerged with reports of increased plasma
F2-isoprostanes and advanced oxidative protein products
(AOPP), as indices of lipid and protein oxidation, in cord
blood [27, 32].
2. Oxidative Stress in the Prenatal Period
Embryos and fetuses have a relative immaturity of the
antioxidant system that facilitates the exposure to the damag-
ing eﬀects of an OS condition [12]. ROS highly aﬀect embryo
and fetus development, thus causing diﬀerent diseases with a
common pathophysiology based on antioxidant impairment
and FR overproduction.
Some conditions of pregnancy are speciﬁc triggers for
an overload of FRs, thus setting an adverse intrauterine
environment with subsequent fetal development impair-
ment [33, 34]. Morphological and immunohistochemical
analyses show an increased oxidative damage in placental
tissues obtained from early spontaneous abortion compared
with normal controls [35]. On the other hand, impaired
extravillous trophoblast invasion and insuﬃcient uterine
artery remodeling, associated with the onset of preeclampsia
(PE), lead to highly resistant spiral arteries and to ischemia/
reperfusion of placenta [36, 37]. Oxidase activity was
detected and conﬁned to the microvillus membrane of syncy-
tiotrophoblast and might be abnormally regulated in PE
pregnancies [33]. A deregulation of phospholipases A2 could
potentially be implicated in freeing F2-isoP, which could
participate in local hypertension observed in the PE placenta
through the thromboxane pathway. Indeed, free F2-isoP was
found to be signiﬁcantly higher in preeclamptic woman than
normotensive controls [38]. PE is not only an endothelial
disease but also a consequence of a wider range of systemic
inﬂammatory network responses [39]. Activated macro-
phages, neutrophils, and Th1 cells can inﬁltrate into renal
and other tissues in women with PE [39]. Systemic inﬂam-
mation and circulating antiangiogenic factors may ultimately
end in multiorgan dysfunction if not controlled in a timely
manner [40].
Early-onset PE is almost invariably associated with IUGR
[34]. Despite having distinctive clinical manifestations, there
is an accumulating evidence that the two pathologies have a
common cause: an abnormal placental implantation [41].
This deﬁciency is thought to be associated with placenta
underperfusion, which is a high risk factor for subsequent
OS [42]. In IUGR, OS may hinder the placental neutral
amino acid transport and may reduce the glucose accumula-
tion in the syncytiotrophoblast, all of which decrease the
uptake of critical materials for fetal development [43]. The
relationship between IUGR and OS was reported by several
authors [11, 44, 45]. In particular, neonates with IUGR
showed a signiﬁcant deﬁciency in antioxidant defenses as
well as an increased lipid peroxidation [46]. F2-IsoP, which
represents the main marker of the arachidonic acid peroxida-
tion, was higher in pregnancies with fetal growth restriction
and showed a moderate power on distinguish between
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normal and restricted growth fetuses, when tested on amni-
otic ﬂuid [11].
FRs may also disrupt the amino acid binding to proteins
and polyunsaturated fatty acids of lipid membranes, thus
causing cell dysfunction, modiﬁcation of chorioamniotic
biology, and, ﬁnally, the premature rupture of membranes
[11]. For conﬁrmation, higher levels of F2-IsoP were found
in amniotic ﬂuid of mothers with premature rupture of
membranes, compared with control pregnancies [47].
Diabetes and obesity may induce OS in pregnancy, which
in turn may cause biochemical disturbances of the fetus and
newborn [48, 49]. In diabetes mellitus, ROS are produced
in excess due to the prolonged periods of hyperglycemia,
which is known to cause nonenzymatic glycation of plasma
proteins [23]. Moreover, glucose undergoes autooxidation,
thus forming FR hydroxilic anions that overwhelm the
antioxidant cellular responses. The high blood glucose levels
can aﬀect the surrounding vasculature, causing the endothe-
lium to be more sensitive to FRs [50]. To date, in diabetes
experimental models, an increased ROS generation was
highlighted in the embryos, fetuses, and placentas [51–53].
This increase in intrauterine OS during embryonic and
feto-placental development has been associated with an
impaired organogenesis [54]. A detrimental state of OS
may be inherited at birth by the intrauterine environment.
3. Free Radical-Related Diseases of the
Newborn: Overview
Newborns are particularly prone to OS due to the exposure to
conditions that can cause a burden of FRs. Preterms have
weak antioxidant defenses that are not able to counteract
the harmful eﬀects of FRs. Moreover, frequent condition
such as ischemia, hypoxia-reperfusion, infection, and inﬂam-
mation are triggers capable to produce high levels of FRs,
thus perturbing the normal redox balance and shifting cells
into a state of OS [55]. Blood transfusions, increased levels
of nonprotein-bound iron (NPBI), xenobiotics, drugs, and
hyperoxia are other potential sources of FR generation.
Cellular, tissue, and organ damages, involving kidney,
retina, lung, and bowel injuries, have been related with OS
biomarker levels in cord blood [27], thus leading to the
hypothesis of free radical-related diseases of prematurity.
Intraventricular hemorrhage, retinopathy of prematurity,
bronchopulmonary dysplasia, and necrotizing enterocolitis
have been already included in this group of conditions [26].
Later in this work, the last evidences supporting the relation-
ship between OS and diseases of prematurity will be updated.
Moreover, other conditions such as kidney damage and
hemolysis will be reviewed and discussed.
3.1. Intraventricular Hemorrhage. Intraventricular hemor-
rhage (IVH) in very preterm infants is a common disease
associated with long-term consequences [56]. The hemor-
rhage typically involves the periventricular germinal matrix
(GM). Pathogenesis of GMH-IVH is multifactorial, complex,
and heterogeneous. An inherent fragility of the GM vascula-
ture predisposes to hemorrhage, and ﬂuctuation in the
cerebral blood ﬂow induces the rupture of blood vessels
(Figure 2). Platelet or coagulation disorders might accentuate
and perpetuate the hemorrhage [57]. The inherent fragility of
the germinal matrix vasculature may be further exacerbated
following hypoxia, but the precise eﬀects on cerebral blood
vessels remain poorly understood [58]. Recently, more
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Figure 2: Schematic representation of vascular cerebral injury.
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detailed analyses have demonstrated the role of OS in this
context [59]. During hypoxia, FR production increases,
enhancing all the pathways implicated in microvascular
damage and dysfunction. H2O2 and nitric oxide radicals
(NO•) are able to activate the soluble enzyme guanylate
cyclase, which catalyzes the formation of the cyclic “second
messenger” guanosine monophosphate (cGMP). cGMP
modulates the function of protein kinases, ion channels,
and other important targets, leading to altered dilatation of
arterioles, enhanced ﬂuid ﬁltration, leukocyte plugging in
capillaries, and release of inﬂammatory mediators and
platelet activation [60]. The oxidative events that trigger
the initiation of bleeding into the germinal matrix pro-
mote a cascade leading to the disruption of tight junctions,
to the increased blood-brain barrier permeability, and to
microglial activation within the developing periventricular
white matter. These events are mediated by cytokines
(IL-1β and TNF-α), VEGF, and NO. Finally, reactive
microglia release ROS, which in turn not only contribute
to endothelial damage but also alter hemostasis and
increase anaerobic metabolism [61]. In our previous study,
we found increased plasma levels of total hydroperoxides
(TH), advanced oxidation protein products (AOPP), and
particularly NPBI in newborn who developed IVH [27].
Hypoxia and ischemia are the most important source of
nonprotein-bound iron (NPBI) [62]. Moreover, the latter’s
conditions also supply redox-cycling iron, enhancing NPBI
release into plasma [63]. Even higher increment of NPBI
was described during reperfusion phase by erythrocyte
releasing [64]. Due to low transferrin levels, the decreased
transferrin iron-binding capacity, and low levels of cerulo-
plasmin and ferroxidase activities, premature infants may
be particularly prone to an exaggerated generation of
NPBI [65–68]. In this case, iron is capable of causing
degeneration of endothelial cells [69]. Endothelial cell
injury and dysfunction may additionally contribute to the
inﬂammatory response and alteration in coagulation,
through loss of normal endothelial NO production [70].
Other potential implications of iron overload are acute
impairment of endothelium-dependent ﬂow-mediated
vasodilation [71], loss of tight junction proteins, degenera-
tion of endothelial cells, and opening of the blood-brain
barrier [69]. Separation of endothelial tight junctions, loss
of endothelial attachment to the basement membrane,
endothelial blebbing, and endothelial necrosis have been
described in the cerebral vasculature following ischemic
injury [72]. The progression of endothelial dysregulation
can contribute to the ongoing pathogenesis of IVH.
3.2. Retinopathy of Prematurity. Retinopathy of prematurity
(ROP) is the major cause of visual impairment and blindness
in premature neonates worldwide [73]. ROP-associated
blindness incidence has been reported to be lower than 10%
of extremely preterm born children, but in some low- and
middle-income countries, the incidence can reach the 40%
[74, 75]. Normally, the peripheral retinal vascularization
keeps developing until the fetus is near to full-term.
ROP occurs in two phases: the vascular attenuation phase
(phase I) and the ﬁbrovascular proliferative phase (phase
II). In phase I, a cessation of normal retinal vasculariza-
tion is driven by hyperoxia, while in phase II, hypoxia
renews vascularization. In both of these cases, VEGF
plays a major role but in an opposite manner [76]. During
hyperoxic phase I, VEGF is suppressed arresting the normal
retinal vascularization and leading to the loss of some devel-
oping vessels. Later in retinal development, the oxygen need
increases and a hypoxic condition arises. VEGF production
begins in response to this hypoxia, thus giving rise to retinal
neovascularization in the outer border, between vascularized
and nonvascularized retinas [77]. The action of VEGF
depends on insulin-like growth factor-1 (IGF-1) [78]. Fetal
IGF-1 precipitously falls after premature birth and increases
due to the newborn’s maturation, thus contributing to the
later neovascularization process.
It is not clear why some babies develop severe ROP
whereas other babies with similar clinical characteristics do
not progress to a severe stage. Genetic factors in addition to
prematurity or environmental conditions may be responsible
of the development and progression of ROP.
OS may represent a key mechanism in this diﬀerent
individual response, depending from each own redox state.
Diﬀerent from VEGF, OS acts in a continuum manner into
ROP pathophysiology through intracellular ROS generation,
which acts as signaling eﬀectors. Several experimental studies
have deepened our understanding of the role of oxidative and
nitrosative compounds on ROP. In these studies, crosstalk
among inﬂammatory, metabolic, and angiogenic pathways
showed a trigger eﬀect on pathologic or physiologic intracel-
lular oxidative signaling mechanisms [79].
During phase I, oxygen and overall hyperoxia are
fundamental factors, with a direct relationship between a
high-oxygen saturation and ROP [77]. Nitrosative stress
through ONOO– generation may lead to hyperoxia-induced
apoptosis [78] which was found to be implicated in neuro-
glial injury [79] and vaso-obliteration in “oxygen-induced
retinopathy” (OIR) models [80]. Transcription factor, Nrf2,
showed an antioxidant protection against hyperoxia-
induced endothelial loss in OIR and increases avascular
retina [81].
In phase II OIR models, hypoxia- or oxidative-induced
factors mediated the overexpression of VEGF signaling
through VEGF receptor 2 (VEGF2). Overactive VEGFR2
then triggered downstream signaling events that disoriented
endothelial cell divisions and enabled them to grow outside
the plane of the retina rather than within the retina [82–84].
In this context, ROS were mainly produced by Nox [85]. Var-
ious isoforms of Nox have been implicated, including Nox-1
[86], Nox-2 [87], and Nox-4 [88]. Controversially, Nox is the
key enzyme in leukocytes which serves to ﬁght invading
microorganisms; hence, inhibiting Nox may have unwanted
consequences. Nitric oxide (NO) can also have beneﬁcial
eﬀects on endothelial cells as a vasodilator, but NO may be
capable to generate ONOO– in the presence of high concen-
trations of superoxide radical. Thus, we are presented
with a double-edged sword and a balance between, or a
speciﬁc targeting of, oxidative/nitrosative eﬀects.
Clinical studies supported the risk of oxygen and
hyperoxia in ROP pathogenesis, thus describing how O2
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administration in delivery room was signiﬁcantly associated
with the development of ROP [89]. Very high concentrations
of hypoxanthine, which is produced during hypoxia/reperfu-
sion, were found in the eyes of babies at risk of developing
ROP [90].
It has been shown that the retinal antioxidant and
chelator enzyme content is low in ROP cases [91]. Enhancing
endogenous or exogenous antioxidant power may help in
counteracting OS-related injury [92, 93]. Protective eﬀects
have been shown by giving the potent antioxidant D-
penicillamine and vitamin E [94], but several further studies
are needed to properly analyze other promising antioxidant
agents (Table 1).
3.3. Bronchopulmonary Dysplasia. Bronchopulmonary
dysplasia (BPD) is the most common adverse respiratory
outcome in very preterm neonates [95, 96]. Originally,
“old” BPD was deﬁned based on lung injury occurring in
premature infants born between 29 and 32 weeks of
postmenstrual age (PMA), due to their respiratory distress
syndrome (RDS) requiring oxygen supplementation and
especially mechanical ventilation [97]. Later, the introduc-
tion of maternal corticosteroids [98] and surfactant replace-
ment therapy [99] resulted in a diﬀerent disease phenotype
(“new” BPD) that was seen in younger preterm infants
(below 29 weeks PMA), based on impaired alveolar and
capillary development of the immature lungs [96]. Depend-
ing on the cohort and deﬁnition used, the overall incidence
variates between 5 and 68% and increases signiﬁcantly with
declining gestational age [100]. Prematurity, oxygen toxicity,
inﬂammation, mechanical ventilation, and surfactant deﬁcit
are major factors contributing to the pathogenesis [101].
Recently, much more importance has given to prenatal
environment [102]. In example, preeclampsia alone has been
deﬁned as an independent risk factor for the subsequent
development of BPD [103]. The generation of FR is one
Table 1: Antioxidants and diseases: clinical trials.
Disease Antioxidant Outcome References
BPD
Lutein Possible positive association between lutein and respiratory health Melo van Lent, Leermakers; 2016
iNO+ vitamin A
Reduced the incidence of BPD and BPD+ death and improved
neurocognitive outcomes at 1 year in the 500–749 g birth weight group
Gadhia, Cutter; 2014
Recombinant
human SOD
Reduced early pulmonary injury, resulting in improved
clinical status at 1 year corrected age
Multiple intratracheal doses of rhSOD increase the concentration and
activity of the enzyme in serum, tracheal aspirate, and urine
Davis, Parad; 2003
Davis, Rosenfeld; 1997
Melatonin
Newborns who developed BPD had levels of IL-6, IL-8, TNF-alpha,
and nitrite/nitrate values much higher than those in children
who did not develop BPD
Gitto et al.; Pineal Res; 2004
Vitamin A Vitamin A supplementation does not reduce the incidence of BPD
Gawronski CA, Gawronski KM,
Ann Pharmacother; 2016
NEC
L-Arginine
Enteral L-arginine supplementation appears to reduce the
incidence of stage III NEC in VLBW infant
Polycarpou et al., 2013
Pentoxifylline
Pentoxifylline did not change the risk of development of NEC
in neonates with sepsis
Pammi et al., 2015
Melatonin
Melatonin administration as an adjuvant therapy in neonatal
NEC treatment is associated with improvement of clinical
and laboratory outcome
[130]
ROP
Vitamin A
A trend towards reduced incidence of retinopathy of prematurity in
vitamin A-supplemented infants
Darlow et al., Cochrane Database
Syst Rev; 2002
Vitamin E
There was a 52% reduction in the incidence of stage 3+ ROP
in VLBW infants
In VLBW infants, vitamin E supplementation signiﬁcantly increased the
risk of sepsis and reduced the risk of severe retinopathy and blindness
[94]; Brion et al., Cochrane
Database Syst Rev; 2003
D-Penicillamine
Six of the 70 surviving control infants and none of the 71 surviving treated
infants had ROP stage II or greater Prophylactic enterally administered
DPA does not prevent any stage ROP
Lakatos et al., Acta Paediatr; 1986
Tandon et al., Acta Paediatr; 2010
Recombinant
human SOD
rhSOD reduces the risk of developing ROP in extremely low
gestational age newborn
Parad et al., Neonatology; 2012
Lutein
There were no diﬀerences in the incidence of ROP at any stage
between groups
No signiﬁcant eﬀect was seen on threshold ROP
Romagnoli et al., J Matern Fetal
Neonatal Med.; 2011
Manzoni et al., Am J Perinatol;
2013
Allopurinol Failure of allopurinol prophylaxis to prevent ROP
Russel et al., Arch Dis Child Fetal
Neonatal Ed; 1995
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common pathway shared by these insults. Moreover, inade-
quate nutrition and how the baby is ventilated participate
to the increase of OS [104].
“Old” BPD is characterized by a tissue remodeling
process that has been divided into diﬀerent phases, ending
up in the chronic phase with an increased number of ﬁbro-
blasts and ﬁbrotic areas. Matrix metalloproteinases (MMPs)
are important in ﬁbrotic processes, and the balance between
MMPs and their inhibitors normally drives the development
of ﬁbrosis. MMP expression is regulated at the transcrip-
tional level by cytokines, growth factors, and extracellular
matrix components. OS increases both MMPs and their
inhibitors, thus causing a disruption of the extracellular
matrix [104].
The “new” BPD was observed to have less ﬁbrotic
component and a more delayed alveolar development than
the older counterpart [105]. Many authors suggested that
an ongoing inﬂammatory process could be the prior mecha-
nism in this “atypical” BPD [101, 106]. The release of inﬂam-
matory mediators can stimulate the endothelium to produce
adhesion molecules, resulting in transendothelial cytokine
migration [107]. The increased cytokine concentration
could therefore enter in a “ﬁnal common pathway” leading
to OS-related lung damage, whether triggered by infection
(antenatal or postnatal) or by lung stretching (airways,
alveoli, basement membrane, and pulmonary capillary
endothelium) [106]. Supporting this theory, there was an
increased concentration of TNF-α and other proinﬂamma-
tory cytokines in tracheal secretions of mechanical ventilated
newborns with BPD. Phagocyte number and interleukin
concentrations were also found to be elevated in bronchoal-
veolar lavage ﬂuid of infants with BPD [108]. The phagocytic
cells in the lung mediate their antimicrobial functions
through the release of lysozymes, peroxidases, and proteases,
but in addition, ROS and NO were released. Activated neu-
trophils and pulmonary type II cells are also important
inducers of the Fenton reaction, which lead to a greater
ROS generation [105].
3.4. Necrotizing Enterocolitis. Necrotizing enterocolitis
(NEC), a syndrome of intestinal ischemic necrosis, is the
most common gastrointestinal emergency in preterm infants
and results in signiﬁcant morbidity and mortality [109, 110].
NEC has a multifactorial etiology including low gestational
age, low birth weight, low Apgar scores, hyaline membrane
disease, formula feeding, umbilical vessel catheterization,
and intestinal ischemia. Other risk factors are the pro-
longed antibiotic exposure, the sensitization to cow milk
proteins, the genetic polymorphism in vascular endothelial
grow factor, interleukin-10, and interleukin-12 [111–114].
Among them, a common synergistic eﬀect of OS was
described [115].
When epithelial gut cells are exposed to enteral feeding,
the increased metabolic OS tips the population toward
apoptosis, inﬂammation, bacterial activation, and eventual
necrosis [116]. Mitochondria are the major source of
intestinal apoptotic signaling, which is activated during OS
condition [117]. OS also causes the partial inactivation of
cyclooxygenase-1 (COX-1) and reduces the generation of
gastroprotective prostaglandins (PG) that are known to
inhibit gastric acid secretion, increase mucosal blood ﬂow,
and stimulate mucus-HCO3 secretion [118]. Ischemia and
low-oxygen tension reduce the electron transport chain with
subsequent excessive generation of hydroxyl radical (•OH),
causing peroxidation of lipid cellular membranes and
oxidative damage to proteins and other macromolecules. It
is noteworthy that glutathione peroxidase (GPx), a major
antioxidant enzyme in the gastric mucosa, was found to be
inactivated during stress probably by excessively generated
•OH causing oxidative damage of GPx. This phenomenon
seems to play a signiﬁcant role in stress-induced gastric
ulceration [119].
These triggering mechanisms result in signiﬁcant inﬂam-
mation of the intestinal tissues, release of inﬂammatory
mediators, and downregulation of cellular growth factors.
The proinﬂammatory cytokines activate a cascade of events
leading to the eventual breakdown of the intestinal mucosal
barrier and to severe NEC in some cases [120]. The
immaturity of the gastrointestinal tract in preterm infants
may also contribute to NEC development [121]. Toll-like
receptor 4 (TLR4) expression is downregulated in the mature
intestinal epithelium upon stimulation by Gram-negative
lipopolysaccharide but is increased in the immature intesti-
nal epithelium, leading to an exaggerated proinﬂammatory
response through upregulation of the NF-κB pathway
[122]. Lipopolysaccharide from Gram-negative bacteria
interacts with TLR4 expressed predominantly by enterocytes.
This interaction results in the breakdown of the gut barrier
and allows for pathogenic bacterial translocation. A proin-
ﬂammatory response follows resulting in increased produc-
tion of proinﬂammatory cytokines (IL-6, IL-8, and TNF) as
well as increased Th17 cells and a decrease in the number
of T regulatory cells. The combination of these cellular
responses with TLR4 signaling results in a profound inﬂam-
matory response [123, 124]. Moreover, TLR4 decreases the
expression of endothelial nitric oxide synthase (eNOS),
thereby reducing the formation of nitric oxide (NO), an
important vasodilator. All this results in intestinal ischemia
and subsequent NEC.
We found a strong association between NEC and cord
blood concentrations of AOPP, NPBI, and TH, showing a
clear correlation between intrauterine OS events and the risk
of developing NEC [125]. Ozdemir et al. reported a signiﬁ-
cant increase of intestinal malondialdehyde (MDA) in
preterm infants with NEC [126]. All-trans retinoic acid treat-
ment reduced the intestinal MDA elevation, suggesting an
active lipid peroxidation in NEC disease [126]. Consistent
with these results, the administration of antioxidant drugs
has been shown to reduce intestinal mucosa damaged by
ischemia or inﬂammation [127, 128]. TNF-α and IL-1β were
reduced in animal model aﬀected by NEC and treated with
melatonin [129], a highly eﬀective antioxidant and FR
scavenger. Melatonin also showed beneﬁcial eﬀects as an
adjuvant therapy in preterm newborns [130].
All these data establish the importance of perinatal
oxidative insults in injured intestinal epithelial cells, thus
proving a reasonable basis for developing new interventions
to interrupt those mechanisms.
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3.5. Renal Damage. The kidney is often severely damaged
after asphyxia, but few data are available on renal oxidative
damage in the newborn infant. Experimental studies show a
high basal rate of aerobic metabolism in renal tissue, which
suggests that the kidneys would be a primary target for this
form of injury [131, 132]. The nephron of the mammalian
kidney is composed of several cert types, each with distinct
morphological, biochemical, and functional characteristics.
One consequence of this heterogeneity is a diﬀerent suscepti-
bility to various forms of chemical and pathological injury.
For example, medullary thick ascending limb cells and the
pars recta of the proximal tubule are especially sensitive to
injury after hypoxia or ischemia. FR-mediated lipid peroxi-
dation has been implicated as a mechanism of tissue injury
during ischemia. Lipid peroxidation products aﬀect renal
function directly by causing renal vasoconstriction or
decreasing the glomerular capillary ultraﬁltration coeﬃcient
and thus the glomerular ﬁltration rate [133].
The activation of the phosphoinositide-3-kinase- (PI3K-)
Akt-nuclear factor- (NF-) κB axis was detected in this rat
kidney ischemia reperfusion injury model [134]. A study by
Weinberg et al. on hypoxic injury to isolated renal proximal
tubules showed that exogenous GSH has a protective eﬀect
[135]. Renal GSH content is decreased by hypoxia or
ischemia, and the decline is most rapid immediately after
the cessation of blood ﬂow [136]. Research on the gluta-
thione system has shown that while total GSH levels tend
to decrease, GSSG levels remain constant during the pro-
gression of chronic renal failure [137], suggesting that
the kidney plays an important role in the maintenance
of GSH concentrations in blood. Cellular responses to
OS include the induction of heme oxygenase (HO) that
helps to attenuate the adverse eﬀects of these environmental
factors [138].
The induction of HO and increased ferritin synthesis
may be protective in renal oxidative injury, in which
increased amounts of noncatalytic-free iron have a critical
role or in circumstances in which oxidative cell injury is
associated with increased intracellular content of heme. The
release of iron from heme proteins contributes to oxidative
kidney damage through hydroxyl radical generation and
lipid peroxidation [139].
Increased HO activity allows the degradation of any
heme released from endogenous oxidatively denatured
heme proteins, whereas increased tissue ferritin-bound
iron released from heme [140]. Administration of the iron
chelator desferrioxamine during reperfusion is reported to
limit postischemic renal dysfunction by an eﬀect that
appears to take place in the urinary space or along the
adjacent brush border membrane. Markers of renal oxida-
tive stress have been proposed [141]. Advanced oxidative
protein products seem to be a reliable marker of the
degree of oxidant-mediated protein damage and the poten-
tial eﬃciency of antioxidant therapy. Similarly, advanced
glycation end products are enhanced during renal failure
and are the result of the nonenzymatic reaction linking a
protein amino group with a glucose-derived aldehyde
group [142].
3.6. Oxidative Hemolysis. Red blood cells (RBC) have a
wide array of antioxidant enzymes defending against
attacks by FRs. Superoxide dismutase (SOD), catalase (CT),
and glutathione peroxidase (GPX) represent great antioxi-
dant resources of these cells against stressors associated with
prematurity [143]. Otherwise, after exposure of RBCs to OS,
a rapid loss of activity of age-dependent enzymes from
reticulocytes occurs probably due to proteolysis. Various
experiments of hypoxia or hypoxia-reoxygenation in vitro
reported increased Heinz body formation, increased oxida-
tion products of hemoglobin, and increased intraerythrocyte
hydrogen peroxide generation suggesting the increased
susceptibility of red blood cells to the oxidative damage
(Figure 3) [144–146]. Our extensive investigations demon-
strated the key role of OS and iron release in a reactive
form via the Fenton reaction in the erythrocytes. When
erythrocytes were incubated in medium containing
Hb
oxyHb
methHb
Cell swelling
H2O2−
O2−
OH•
NPBI
Red blood cell
hyperpolarization
Membrane KCI−
KCI-
Na+
Na+
Hemolysis
Lipid peroxidation
Free
radicals
Red cell
OS
Fenton
Ca++
Ca ++
reaction
Figure 3: Schematic representation of oxidative red blood cell injury.
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oxidizing agents, iron release and the Fenton reaction led
to the formation of the hydroxyl radical [147, 148]. Iron
is released from hemoglobin or its derivatives, and the
release is accompanied by methemoglobin formation. The
iron diﬀused from erythrocytes into the incubation
medium. Such diﬀusion, together with the higher suscepti-
bility to release iron in newborn erythrocytes, could explain
the appearance of plasma-free iron in newborns. Signiﬁcant
positive correlations were found between plasma-free iron
and isoprostane levels in newborns, supporting the prooxi-
dant role of free iron [149]. The higher free iron concentra-
tion, the higher lipid and protein peroxidation rate [150].
The erythrocytes are therefore a target of extracellular FR
and at the same time generators of OS. The eryptosis should
be considered as a cause of hemolysis when there is no
evidence of an immune-mediated hemolytic anemia, no
morphologic or laboratory data to suggest a problem of the
red cell membrane, and no evidence of a quantitative or qual-
itative defect in hemoglobin synthesis in the newborns [146].
4. Conclusions
The existence of a redox homeostasis is essential for normal
health and survival of the cell. When an unbalance between
prooxidant and antioxidant factors occurs, OS is produced
leading to cellular and tissue damage. The newborn,
especially if preterm, is highly prone to OS and to the toxic
eﬀect of FRs. Taking advantage of the wealth of ﬁndings
in perinatal OS researches, the relationship between OS-
related mechanisms of injury and the so-called “free
radical-related diseases of prematurity” can be considered
irrefutable. Antioxidants may represent a very important
weapon to ﬁght this common way of damage. Collaterally,
the development of biomarker OS panel has a very attractive
prospect for future clinical application, in terms of preven-
tion and response to therapy. Although much evidence
already exists, more study is needed to eradicate the barrier
hindering the widespread use of biomarkers. To conclude,
it is no longer a long way from bench to bedside for antioxi-
dant therapy and OS biomarkers in neonatology.
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